Header Logo

Connection

Kathleen Moore to MAP Kinase Kinase Kinases

Back to Details
This is a "connection" page, showing publications Kathleen Moore has written about MAP Kinase Kinase Kinases.
Kathleen Moore
Connection Strength
0.165
MAP Kinase Kinase Kinases
  1. Safety lead-in of the MEK inhibitor trametinib in combination with GSK2141795, an AKT inhibitor, in patients with recurrent endometrial cancer: An NRG Oncology/GOG study. Gynecol Oncol. 2019 12; 155(3):420-428.
    View in: PubMed
    Score: 0.165
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.